Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 167

1.

Plasma beta amyloid and the risk of Alzheimer disease and dementia in elderly men: a prospective, population-based cohort study.

Sundelöf J, Giedraitis V, Irizarry MC, Sundström J, Ingelsson E, Rönnemaa E, Arnlöv J, Gunnarsson MD, Hyman BT, Basun H, Ingelsson M, Lannfelt L, Kilander L.

Arch Neurol. 2008 Feb;65(2):256-63. doi: 10.1001/archneurol.2007.57.

PMID:
18268197
2.

Evaluation of plasma Aβ as predictor of Alzheimer's disease in older individuals without dementia: a population-based study.

Hansson O, Stomrud E, Vanmechelen E, Östling S, Gustafson DR, Zetterberg H, Blennow K, Skoog I.

J Alzheimers Dis. 2012;28(1):231-8. doi: 10.3233/JAD-2011-111418.

PMID:
21955816
3.

Serum cystatin C and the risk of Alzheimer disease in elderly men.

Sundelöf J, Arnlöv J, Ingelsson E, Sundström J, Basu S, Zethelius B, Larsson A, Irizarry MC, Giedraitis V, Rönnemaa E, Degerman-Gunnarsson M, Hyman BT, Basun H, Kilander L, Lannfelt L.

Neurology. 2008 Sep 30;71(14):1072-9. doi: 10.1212/01.wnl.0000326894.40353.93.

4.

Plasma amyloid-β levels and prognosis in incident dementia cases of the 3-City Study.

Gabelle A, Richard F, Gutierrez LA, Schraen S, Delva F, Rouaud O, Buée L, Dartigues JF, Touchon J, Lambert JC, Berr C.

J Alzheimers Dis. 2013;33(2):381-91. doi: 10.3233/JAD-2012-121147.

5.

Midlife blood pressure, plasma β-amyloid, and the risk for Alzheimer disease: the Honolulu Asia Aging Study.

Shah NS, Vidal JS, Masaki K, Petrovitch H, Ross GW, Tilley C, DeMattos RB, Tracy RP, White LR, Launer LJ.

Hypertension. 2012 Apr;59(4):780-6. doi: 10.1161/HYPERTENSIONAHA.111.178962. Epub 2012 Mar 5.

6.

Serum Abeta levels as predictors of conversion to mild cognitive impairment/Alzheimer disease in an ADAPT subcohort.

Abdullah L, Luis C, Paris D, Mouzon B, Ait-Ghezala G, Keegan AP, Wang D, Crawford F, Mullan M.

Mol Med. 2009 Nov-Dec;15(11-12):432-7. doi: 10.2119/molmed.2009.00083. Epub 2009 Aug 18.

7.

Elevated plasma beta-amyloid peptide Abeta(42) levels, incident dementia, and mortality in Down syndrome.

Schupf N, Patel B, Pang D, Zigman WB, Silverman W, Mehta PD, Mayeux R.

Arch Neurol. 2007 Jul;64(7):1007-13.

8.

Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease.

Graff-Radford NR, Crook JE, Lucas J, Boeve BF, Knopman DS, Ivnik RJ, Smith GE, Younkin LH, Petersen RC, Younkin SG.

Arch Neurol. 2007 Mar;64(3):354-62. Erratum in: Arch Neurol. 2007 Sep;64(9):1246.

PMID:
17353377
9.

Plasma amyloid-β as a predictor of dementia and cognitive decline: a systematic review and meta-analysis.

Koyama A, Okereke OI, Yang T, Blacker D, Selkoe DJ, Grodstein F.

Arch Neurol. 2012 Jul;69(7):824-31. Review.

10.

The relationship of plasma Aβ levels to dementia in aging individuals with mild cognitive impairment.

Fei M, Jianghua W, Rujuan M, Wei Z, Qian W.

J Neurol Sci. 2011 Jun 15;305(1-2):92-6. doi: 10.1016/j.jns.2011.03.005. Epub 2011 Mar 26.

PMID:
21440911
11.

Plasma amyloid levels and the risk of AD in normal subjects in the Cardiovascular Health Study.

Lopez OL, Kuller LH, Mehta PD, Becker JT, Gach HM, Sweet RA, Chang YF, Tracy R, DeKosky ST.

Neurology. 2008 May 6;70(19):1664-71. doi: 10.1212/01.wnl.0000306696.82017.66. Epub 2008 Apr 9.

12.

Plasma amyloid β, depression, and dementia in community-dwelling elderly.

Direk N, Schrijvers EM, de Bruijn RF, Mirza S, Hofman A, Ikram MA, Tiemeier H.

J Psychiatr Res. 2013 Apr;47(4):479-85. doi: 10.1016/j.jpsychires.2012.12.008. Epub 2013 Jan 11.

13.

Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study.

van Oijen M, Hofman A, Soares HD, Koudstaal PJ, Breteler MM.

Lancet Neurol. 2006 Aug;5(8):655-60.

PMID:
16857570
14.

Plasma amyloid-β and risk of Alzheimer's disease in the Framingham Heart Study.

Chouraki V, Beiser A, Younkin L, Preis SR, Weinstein G, Hansson O, Skoog I, Lambert JC, Au R, Launer L, Wolf PA, Younkin S, Seshadri S.

Alzheimers Dement. 2015 Mar;11(3):249-57.e1. doi: 10.1016/j.jalz.2014.07.001. Epub 2014 Sep 10.

15.

Association of plasma leptin levels with incident Alzheimer disease and MRI measures of brain aging.

Lieb W, Beiser AS, Vasan RS, Tan ZS, Au R, Harris TB, Roubenoff R, Auerbach S, DeCarli C, Wolf PA, Seshadri S.

JAMA. 2009 Dec 16;302(23):2565-72. doi: 10.1001/jama.2009.1836.

16.

Dementia and Alzheimer disease incidence: a prospective cohort study.

Kukull WA, Higdon R, Bowen JD, McCormick WC, Teri L, Schellenberg GD, van Belle G, Jolley L, Larson EB.

Arch Neurol. 2002 Nov;59(11):1737-46.

PMID:
12433261
17.

Reduced 25-hydroxyvitamin D and risk of Alzheimer's disease and vascular dementia.

Afzal S, Bojesen SE, Nordestgaard BG.

Alzheimers Dement. 2014 May;10(3):296-302. doi: 10.1016/j.jalz.2013.05.1765. Epub 2013 Jul 18.

PMID:
23871764
18.

Biomarkers for insulin resistance and inflammation and the risk for all-cause dementia and alzheimer disease: results from the Framingham Heart Study.

van Himbergen TM, Beiser AS, Ai M, Seshadri S, Otokozawa S, Au R, Thongtang N, Wolf PA, Schaefer EJ.

Arch Neurol. 2012 May;69(5):594-600.

19.

Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults.

Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM.

Arch Neurol. 2007 Mar;64(3):343-9. Epub 2007 Jan 8.

PMID:
17210801
20.

Homocysteine and folate as risk factors for dementia and Alzheimer disease.

Ravaglia G, Forti P, Maioli F, Martelli M, Servadei L, Brunetti N, Porcellini E, Licastro F.

Am J Clin Nutr. 2005 Sep;82(3):636-43.

Items per page

Supplemental Content

Write to the Help Desk